Abu Dhabi’s TII Launches Falcon-H1 Arabic, Establishing the World’s Leading Arabic AI Model January 5, 2026 Based on new hybrid-architecture, models deliver higher accuracy while running on smaller parameter sizes Launch underscores UAE push to compete with global AI leaders in high-performance language models
Westlake Strengthens Global Compounds Portfolio With Acquisition of ACI Compounding Solutions Business January 5, 2026 Westlake Corporation (NYSE: WLK) (“Westlake”) announced today that it has completed the acquisition of the global compounding solutions businesses of the ACI/Perplastic Group (collectively, “ACI”). Headquartered in Portugal, ACI is a global manufacturer of specialty materials, primarily serving the wire and cable sectors. “The integration of ACI with Westlake’s compounding operations represents a strong strategic [...]
WP Engine Appoints Google Veteran Thierry Muller as Vice President of AI Products January 5, 2026 Accomplished leader brings extensive technical acumen, artificial intelligence experience and a strong track record of driving innovation
TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models January 5, 2026 Falcon H1R 7B Packs Advanced Reasoning into a Compact 7 Billion Parameter Model Optimized for Speed and Efficiency TII’s Latest AI Model Outperforms Larger Rivals from Microsoft, Alibaba, and NVIDIA on Key Benchmarks
Nex Playground Showcases Future of Active Play at CES and an Early “First Look” at its 2026 Product Roadmap January 5, 2026 Following a Blockbuster Holiday Season, the Company Shares International Growth Plan, New Sports Experiences, Expanded Content Lineup, and Connected Playdate Feature
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq January 5, 2026 Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.
Phillips 66 Limited agrees to acquire Lindsey Oil Refinery assets January 5, 2026 Agreement follows Prax Lindsey Oil Refinery Limited’s liquidation and is pending completion subject to satisfaction of closing conditions. Key facilities to be integrated into the Humber Refinery rather than restarting standalone refinery operations at the Lindsey site. Investment will strengthen the Humber Refinery, boost domestic energy security, ensure continued supply of quality fuels to the UK and help secure UK jobs.
Lakestreet Capital Partners Demands Change to Benefit All Shareholders of Palace Capital Plc, the FTSE REIT January 5, 2026 Lakestreet Capital Partners AG (“Lakestreet”), the largest shareholder in Palace Capital Plc (“Palace Capital”) with a 22.53% total shareholding* has this weekend requisitioned a general meeting of Palace Capital to remove its Chairman, Steven Owen and to appoint its founders as directors. Lakestreet is deeply troubled by the excessive amount of remuneration that Steven Owen [...]
Interactive Brokers’ Individual and Hedge Fund Clients Outperformed the S&P 500 on Average in 2025 January 2, 2026 Lower costs, global market access, and efficient execution contributed to stronger client outcomes.
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference December 30, 2025 Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, Jan. 13, 2026 at 10:30 a.m. PST (1:30 p.m. EST/6:30 p.m. GMT). The live webcast may be accessed under the [...]
